COSCIENS Biopharma (CSCI) Competitors $2.61 -0.47 (-15.26%) Closing price 09/3/2025Extended Trading$2.61 0.00 (0.00%) As of 09/3/2025 06:18 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsHeadlinesSEC FilingsTrendsBuy This Stock CSCI vs. JATT, NLTX, ITRM, OKUR, RENB, MAAQ, TENX, LEXX, DARE, and RVPHShould you be buying COSCIENS Biopharma stock or one of its competitors? The main competitors of COSCIENS Biopharma include JATT Acquisition (JATT), Neoleukin Therapeutics (NLTX), Iterum Therapeutics (ITRM), OnKure Therapeutics (OKUR), Renovaro (RENB), Mana Capital Acquisition (MAAQ), Tenax Therapeutics (TENX), Lexaria Bioscience (LEXX), Dare Bioscience (DARE), and Reviva Pharmaceuticals (RVPH). These companies are all part of the "pharmaceutical products" industry. COSCIENS Biopharma vs. Its Competitors JATT Acquisition Neoleukin Therapeutics Iterum Therapeutics OnKure Therapeutics Renovaro Mana Capital Acquisition Tenax Therapeutics Lexaria Bioscience Dare Bioscience Reviva Pharmaceuticals JATT Acquisition (NYSE:JATT) and COSCIENS Biopharma (NASDAQ:CSCI) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their dividends, media sentiment, valuation, institutional ownership, earnings, profitability, risk and analyst recommendations. Does the media favor JATT or CSCI? In the previous week, JATT Acquisition's average media sentiment score of 0.00 equaled COSCIENS Biopharma'saverage media sentiment score. Company Overall Sentiment JATT Acquisition Neutral COSCIENS Biopharma Neutral Is JATT or CSCI more profitable? JATT Acquisition has a net margin of 0.00% compared to COSCIENS Biopharma's net margin of -199.55%. JATT Acquisition's return on equity of -49.58% beat COSCIENS Biopharma's return on equity.Company Net Margins Return on Equity Return on Assets JATT AcquisitionN/A -49.58% 2.84% COSCIENS Biopharma -199.55%-149.49%-54.80% Do institutionals and insiders believe in JATT or CSCI? 48.0% of JATT Acquisition shares are held by institutional investors. Comparatively, 0.7% of COSCIENS Biopharma shares are held by institutional investors. 20.0% of JATT Acquisition shares are held by insiders. Comparatively, 0.1% of COSCIENS Biopharma shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth. Which has higher earnings & valuation, JATT or CSCI? JATT Acquisition has higher earnings, but lower revenue than COSCIENS Biopharma. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioJATT AcquisitionN/AN/A$6.85MN/AN/ACOSCIENS Biopharma$9.44M0.88-$15.31M-$6.01-0.43 SummaryJATT Acquisition beats COSCIENS Biopharma on 6 of the 7 factors compared between the two stocks. Get COSCIENS Biopharma News Delivered to You Automatically Sign up to receive the latest news and ratings for CSCI and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding CSCI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CSCI vs. The Competition Export to ExcelMetricCOSCIENS BiopharmaMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$8.29M$3.07B$5.65B$10.29BDividend YieldN/A2.36%5.68%4.62%P/E Ratio-0.4320.7675.8426.11Price / Sales0.88403.84517.46171.25Price / CashN/A45.9137.5661.52Price / Book0.759.6212.876.30Net Income-$15.31M-$52.73M$3.29B$271.03M7 Day PerformanceN/A0.64%-0.26%-0.15%1 Month Performance-10.92%6.31%3.84%6.41%1 Year Performance-29.84%18.97%68.35%28.81% COSCIENS Biopharma Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CSCICOSCIENS BiopharmaN/A$2.61-15.3%N/A-29.8%$8.29M$9.44M-0.4320Gap DownHigh Trading VolumeJATTJATT AcquisitionN/A$1.92-4.0%N/A-52.6%$33.12MN/A0.003High Trading VolumeNLTXNeoleukin TherapeuticsN/A$17.44-0.1%N/A-58.6%$32.80MN/A-5.6190High Trading VolumeITRMIterum Therapeutics2.7049 of 5 stars$0.69+0.8%$9.00+1,213.9%-29.7%$32.31MN/A-0.8110Gap UpOKUROnKure Therapeutics3.0301 of 5 stars$2.35-1.1%$32.33+1,278.8%N/A$31.73MN/A-0.49N/APositive NewsRENBRenovaro0.817 of 5 stars$0.18-1.6%N/A-64.2%$30.98MN/A-0.2320Trending NewsUpcoming EarningsStock SplitGap DownMAAQMana Capital AcquisitionN/A$3.79-0.9%N/A+1,348.1%$30.79MN/A0.001TENXTenax Therapeutics2.4533 of 5 stars$6.37+4.5%$18.00+182.8%+90.6%$28.75MN/A-6.859Positive NewsHigh Trading VolumeLEXXLexaria Bioscience3.6543 of 5 stars$1.45-1.0%$4.00+176.8%-54.5%$28.26M$460K-2.167Gap DownDAREDare Bioscience2.2165 of 5 stars$2.10-0.2%$10.00+377.3%-33.7%$28.24M$10K-0.9830News CoverageRVPHReviva Pharmaceuticals3.1349 of 5 stars$0.41+3.0%$5.50+1,248.0%-77.0%$27.74MN/A-0.635 Related Companies and Tools Related Companies JATT Competitors NLTX Competitors ITRM Competitors OKUR Competitors RENB Competitors MAAQ Competitors TENX Competitors LEXX Competitors DARE Competitors RVPH Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:CSCI) was last updated on 9/25/2025 by MarketBeat.com Staff From Our PartnersTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredHe Called Nvidia at $1.10. Now, He Says THIS Stock Will…The original Magnificent Seven returned 16,894%—turning $7K into $1.18 million. Now, the man who called Nvi...The Oxford Club | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredCapital Gains Tax Strategies for SeniorsCapital gains taxes can take a bite out of your retirement income—unless you have a smart strategy. From holdi...SmartAsset | SponsoredA New Way to Double Your Retirement Income?Bloomberg reports that a new class of investments is “entering a golden era,” with yields fueling a retail boo...Investors Alley | SponsoredStrange crypto pattern discovered by 40-person research teamSomething unusual is happening inside a 40-person crypto research firm. They're helping 8,000+ ordinary peo...Crypto Swap Profits | SponsoredForget NVDA. Put $1,000 into this stock nowA massive money shift is underway in the AI market. And it's opening up an extraordinary opportunity in a NEW ...Chaikin Analytics | SponsoredIRS Wants Another Check on Sept 15th—What If You Could Keep It Instead?On September 15th, the IRS collects another round of quarterly tax payments—targeting self-employed profession...American Alternative | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding COSCIENS Biopharma Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share COSCIENS Biopharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
